Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
Condition: Leukemia; Lymphoma
MeSH terms: Lymphoma; Leukemia
Study type: Observational

Summary: 
      RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer
      to study in the laboratory may help doctors learn more about diagnosing cancer and determine
      a patient's eligibility for a treatment clinical trial. It may also help the study of cancer
      in the future.

      PURPOSE: This laboratory study is collecting tissue samples from patients with leukemia or
      other blood disorders who are planning to enroll in an ECOG leukemia treatment clinical
      trial.
    

Detailed description: 
      OBJECTIVES:

        -  To provide a mechanism for sample collection and submission for diagnostic review to
           determine eligibility of patients with suspected leukemia or related hematologic
           disorders for enrollment on ECOG leukemia clinical trials.

        -  To obtain baseline samples for correlative studies outlined in parent clinical trials.

      OUTLINE: This is a cohort, multicenter study.

      Patients submit bone marrow and/or blood samples. The samples are studied to determine
      patients' eligibility for ECOG leukemia treatment clinical trials. Samples may be stored for
      future correlative studies related to ECOG treatment clinical trials.
    

Intervention name(s): biologic sample preservation procedure
Intervention type(s): Other
Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Potential candidates for ECOG-ACRIN Leukemia Trials
      
Keywords: accelerated phase chronic myelogenous leukemia; atypical chronic myeloid leukemia, BCR-ABL1 negative; blastic phase chronic myelogenous leukemia; childhood chronic myelogenous leukemia; chronic myelomonocytic leukemia; chronic phase chronic myelogenous leukemia; juvenile myelomonocytic leukemia; meningeal chronic myelogenous leukemia; progressive hairy cell leukemia, initial treatment; recurrent adult acute lymphoblastic leukemia; recurrent adult acute myeloid leukemia; recurrent adult T-cell leukemia/lymphoma; recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; refractory chronic lymphocytic leukemia; refractory hairy cell leukemia; relapsing chronic myelogenous leukemia; stage I adult T-cell leukemia/lymphoma; stage I chronic lymphocytic leukemia; stage II adult T-cell leukemia/lymphoma; stage II chronic lymphocytic leukemia; stage III adult T-cell leukemia/lymphoma; stage III chronic lymphocytic leukemia; stage IV adult T-cell leukemia/lymphoma; stage IV chronic lymphocytic leukemia; untreated adult acute lymphoblastic leukemia; untreated adult acute myeloid leukemia; untreated childhood acute lymphoblastic leukemia; untreated childhood acute myeloid leukemia and other myeloid malignancies; T-cell large granular lymphocyte leukemia; adult acute myeloid leukemia in remission; adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); adult acute myeloid leukemia with t(15;17)(q22;q12); adult acute myeloid leukemia with t(16;16)(p13;q22); adult acute myeloid leukemia with t(8;21)(q22;q22); secondary acute myeloid leukemia; childhood acute myeloid leukemia in remission; acute undifferentiated leukemia; mast cell leukemia; adult acute lymphoblastic leukemia in remission; childhood acute lymphoblastic leukemia in remission; prolymphocytic leukemia; untreated hairy cell leukemia